Skip to main content

Table 1 Characteristics of the patients

From: Efficacy and safety of edoxaban tosylate hydrate 15 mg in the prevention of venous thromboembolism in patients with impaired renal function after orthopedic surgery of the lower extremities

  Edoxaban 15 mg (n = 23) Edoxaban 30 mg (n = 209) p value
Sex
Male 6 (26.1%) 51 (24.4%) 0.80
Female 17 (73.9%) 158 (75.6%)  
Age (years), median (IQR) 81 (77.5–86.5) 71 (65–78)  < 0.01
Body weight (kg), median (IQR) 55 (51.7–65.3) 60.4 (51.0–69.1) 0.31
Body mass index, median (IQR) 23.8 (21.8–29.8) 25.8 (22.1–28.2) 0.73
Creatinine clearance (mL/min), median (IQR) 44.5 (38.1–47.0) 101.4 (79.4–125.1)  < 0.01
Surgical intervention
TKA 10 (43.5%) 65 (31.1%) 0.56
THA 9 (39.1%) 94 (45.0%)  
HFS 3 (13.0%) 25 (12.0%)  
UKA 1 (4.3%) 25 (12.0%)  
Medical history
Intracranial hemorrhage 1 (4.3%) 6 (2.9%) 0.52
Gastrointestinal bleeding 1 (4.3%) 4 (1.9%) 0.41
Venous thromboembolism 0 3 (1.4%) 1.00
Malignant tumor 1 (4.3%) 18 (8.6%) 0.70
Concomitant medication
P-glycoprotein inhibitor 1 (4.3%) 2 (1.0%) 0.27
Antiplatelet agent 3 (13.0%) 11 (5.3%) 0.15
Statin 9 (39.1%) 59 (28.2%) 0.33
Estrogen 0 0 1.00
SERM 0 6 (2.9%) 1.00
Adrenal corticosteroid 2 (8.7%) 8 (3.8%) 0.26
Antipsychotic drug 2 (8.7%) 5 (2.4%) 0.15
Antidepressant 3 (13.0%) 8 (3.8%) 0.08
Tranexamic acid 0 3 (1.4%) 1.00
  1. HFS, hip fracture surgery; SERM, selective estrogen receptor modulator; THA, total hip arthroplasty; TKA, total knee arthroplasty; UKA, knee arthroplasty single granule replacement